Skip to main content
. 2019 Apr 12;12(5):450–458. doi: 10.1111/cts.12633

Figure 1.

Figure 1

Left panel: Kaplan–Meier analysis of overall survival (OS) by treatment group (intention‐to‐treat population). Right panel: Kaplan–Meier analysis of OS by quartiles of exposure at area under the exposure time‐course curve at steady‐state (AUC ss) for the tremelimumab‐treated group with overlaid placebo group OS profile.